WH
WhiteOak Capital Pharma and Healthcare Fund Direct Growth
Latest NAV
+22.13% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.13%
AUM
₹902 Cr
Min SIP
₹100
Min lump sum
₹500
1Y
+22.13%
3Y (ann.)
+0.00%
5Y (ann.)
+0.00%
Launched
Feb 2024
Where the NAV sits & how risky it is
₹17.22
52-week range
at 84%
₹17.22
Low 29 Jan 2026₹13.39
High 23 Sep 2026₹17.97
Risk level
Very High
Low
Very high
NAV history
07 Feb 2024
Since inception
01 Oct 2026
Returns by period
1W
-3.45%
1M
-2.53%
3M
+3.85%
6M
+24.24%
1Y
+22.13%
3Y
+0.00%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹100
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 91.75%
Cash & other 22.92%
Sector split
Country split
Top 5 hold 29.5%
Top 10 hold 44.9%
52 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
9.56%
|
+7.54% |
| 2 | J B Chemicals and Pharmaceuticals
INE572A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
6.80%
|
+21.75% |
| 3 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
4.83%
|
+20.69% |
| 4 | Laurus Labs
INE947Q01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.43%
|
+27.63% |
| 5 | Fortis Healthcare
INE061F01013 |
Healthcare Medical Care Facilities |
India |
3.92%
|
+8.93% |
| 6 | Krishna Institute of Medical Sciences
INE967H01025 |
Healthcare Medical Care Facilities |
India |
3.44%
|
+32.15% |
| 7 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.29%
|
+5.48% |
| 8 | Sai Life Sciences
INE570L01029 |
Healthcare Diagnostics & Research |
India |
3.17%
|
+33.91% |
| 9 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
2.83%
|
+4.75% |
| 10 | Aurobindo Pharma
INE406A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
2.62%
|
+26.61% |
About this scheme
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Fund manager(s): Piyush Baranwal, Ashish Agarwal, Ramesh Mantri, Trupti Agrawal, Shariq Merchant, Dheeresh Pathak
Exit load: No charges for withdrawal
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
06 Feb 2024
Lump-sum min
₹500
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 99.4 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 11.3 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 8.5 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 8.5 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 7.1 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 7.0 pts ahead of this fund